May 18, 2023
Strange things going on, well maybe not.
We’ve paying close attention to the insulin pump space as we see the market at a critical juncture. Medtronic just launched the 780, Tandem’s shares are sinking like a stone, Beta Bionics is about to get FDA approval and Insulet continues to sit firmly upon the Iron Throne. Yet what’s more interesting is how each company is handling their various position.
Let’s start with Medtronic. Although it’s early here in the US the 780 has been available across the pond for some time. Based on everything we have heard and read our belief is the . . .
This content is restricted to subscribers. Please subscribe.
Already have an account? Please login.
